ARW vs NICE

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of just 3/9, indicating significant concerns in profitability, leverage, and operating efficiency. Despite this, the company shows resilience through solid revenue growth (13% YoY), consistent earnings beats (25.62% average surprise over last 4 quarters), and a reasonable Debt/Equity ratio of 0.48. Valuation appears attractive relative to peers with a P/E of 13.08 versus sector average of 89.76 and a Price/Book under 1, though low margins and declining recent EPS growth (-0.8% QoQ) temper optimism. The stock trades below its Graham Number ($157.92) and intrinsic value estimate ($212.3), suggesting potential undervaluation, but weak profitability metrics and lack of Altman Z-Score data limit confidence in financial stability.

NICE presents a classic deep-value opportunity, characterized by a stable Piotroski F-Score of 4/9 and a current price ($101.19) trading below its Graham Number ($117.16) and significantly below its intrinsic value ($280.55). The company maintains an exceptionally clean balance sheet with a Debt/Equity ratio of 0.02 and strong profitability margins. However, this fundamental strength is starkly contrasted by a severe technical collapse, with a 0/100 technical trend and a 57.4% decline over five years. The bullish thesis relies on mean reversion toward fair value, provided the recent earnings misses do not signal a permanent deterioration in growth.